PORT-77
Erythropoietic Protoporphyria (EPP) & X-Linked Protoporphyria (XLP)
Phase 2Active
Key Facts
Indication
Erythropoietic Protoporphyria (EPP) & X-Linked Protoporphyria (XLP)
Phase
Phase 2
Status
Active
Company
About GondolaBio
GondolaBio is a private, clinical-stage biotech company based in San Diego, leveraging a decentralized model to rapidly advance a diverse pipeline of small molecule therapies for genetic diseases. Its lead asset, PORT-77, is a Phase 2 oral ABCG2 inhibitor for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), with FDA Orphan Drug and Fast Track designations. The company's strategy centers on identifying clear genetic markers to target diseases at their source, aiming to address the significant unmet need where only 5% of genetic conditions have approved therapies.
View full company profileTherapeutic Areas
Other Erythropoietic Protoporphyria (EPP) & X-Linked Protoporphyria (XLP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Bitopertin | Disc Medicine | Phase 3 |